1693 related articles for article (PubMed ID: 16010412)
21. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
22. Stimulation of endometrial glandular cells with genistein and daidzein and their effects on ERalpha- and ERbeta-mRNA and protein expresion.
Staar S; Richter DU; Makovitzky J; Briese V; Bergemann C
Anticancer Res; 2005; 25(3A):1713-8. PubMed ID: 16033089
[TBL] [Abstract][Full Text] [Related]
23. CpG methylation of the ERalpha and ERbeta genes in breast cancer.
Kim SJ; Kim TW; Lee SY; Park SJ; Kim HS; Chung KW; Lee ES; Kang HS
Int J Mol Med; 2004 Aug; 14(2):289-93. PubMed ID: 15254780
[TBL] [Abstract][Full Text] [Related]
24. Tamoxifen induces the expression of maspin through estrogen receptor-alpha.
Liu Z; Shi HY; Nawaz Z; Zhang M
Cancer Lett; 2004 Jun; 209(1):55-65. PubMed ID: 15145521
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients.
Altundag O; Altundag K; Gunduz M
Med Hypotheses; 2004; 63(4):684-7. PubMed ID: 15325017
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts.
Hartman J; Lindberg K; Morani A; Inzunza J; Ström A; Gustafsson JA
Cancer Res; 2006 Dec; 66(23):11207-13. PubMed ID: 17145865
[TBL] [Abstract][Full Text] [Related]
27. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
28. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway.
Sauvé K; Lepage J; Sanchez M; Heveker N; Tremblay A
Cancer Res; 2009 Jul; 69(14):5793-800. PubMed ID: 19584281
[TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
30. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells.
Lindberg K; Ström A; Lock JG; Gustafsson JA; Haldosén LA; Helguero LA
J Cell Physiol; 2010 Jan; 222(1):156-67. PubMed ID: 19780039
[TBL] [Abstract][Full Text] [Related]
31. Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells.
Horner-Glister E; Maleki-Dizaji M; Guerin CJ; Johnson SM; Styles J; White IN
J Mol Endocrinol; 2005 Dec; 35(3):421-32. PubMed ID: 16326830
[TBL] [Abstract][Full Text] [Related]
32. Effects of exon-deleted estrogen receptor beta transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines.
Treeck O; Juhasz-Boess I; Lattrich C; Horn F; Goerse R; Ortmann O
Breast Cancer Res Treat; 2008 Aug; 110(3):507-20. PubMed ID: 17876701
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor alpha attenuates transforming growth factor-beta signaling in breast cancer cells independent from agonistic and antagonistic ligands.
Stope MB; Popp SL; Knabbe C; Buck MB
Breast Cancer Res Treat; 2010 Apr; 120(2):357-67. PubMed ID: 19370415
[TBL] [Abstract][Full Text] [Related]
34. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor-beta regulates psoriasin (S100A7) in human breast cancer.
Skliris GP; Lewis A; Emberley E; Peng B; Weebadda WK; Kemp A; Davie JR; Shiu RP; Watson PH; Murphy LC
Breast Cancer Res Treat; 2007 Jul; 104(1):75-85. PubMed ID: 17009105
[TBL] [Abstract][Full Text] [Related]
36. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
Thomas NB; Hutcheson IR; Campbell L; Gee J; Taylor KM; Nicholson RI; Gumbleton M
Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272
[TBL] [Abstract][Full Text] [Related]
37. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer.
Campbell-Thompson M; Lynch IJ; Bhardwaj B
Cancer Res; 2001 Jan; 61(2):632-40. PubMed ID: 11212261
[TBL] [Abstract][Full Text] [Related]
38. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
39. Activity of estradiol and selective estrogen receptor modulators in the mouse N20.1 oligodendrocyte/astrocytes cell line.
Guzmán CB; Deighton-Collins S; Martinez A; Kleerekoper M; Zhao C; Benjamins JA; Skafar DF
Neuro Endocrinol Lett; 2005 Oct; 26(5):526-32. PubMed ID: 16264406
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells.
Zhao C; Matthews J; Tujague M; Wan J; Ström A; Toresson G; Lam EW; Cheng G; Gustafsson JA; Dahlman-Wright K
Cancer Res; 2007 Apr; 67(8):3955-62. PubMed ID: 17440111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
